There could be other bidders, but I still think BristolMS is the...

There could be other bidders, but I still think BristolMS is the most likely.

This is because they already know that CAVATAK improves the efficacy and safety of their drug.

Morgan mention earlier about BMA "...CA21 is worth more to them with it 'demonstrating' a 46% improvements (11%>57%) in combo with Vervoy & CA21..."

But of course it's a 400% plus improvement. Are BMS really likely to find something that does better than that? They could spend decades looking.

ok, it's small trial numbers but very promising early data.

Personally I have sold 30% of my vla, just to diversify and take advantage of other opportunities, but the rest I will hold for a while just in case that counter bid happens.

I must admit that I like the idea that vla management have now forced the hand of potential suitors and that perhaps their plan is not to sell out at $1.75 but to just start the auction.

Out of interest, how soon after selling does a director have to inform the market of a change in their holdings?

Cheers